AbbVie became the latest firm to test the FDA "voucher" strategy as a pathway to success – entering into a $350m deal with United Therapeutics in an effort to get an experimental medicine to the market quicker.
AbbVie/United Therapeutics $350m Voucher Deal: Smart Move?
AbbVie became the latest firm to test the FDA "voucher" strategy as a pathway to success – entering into a $350m deal with United Therapeutics in an effort to get an experimental medicine to the market quicker.
More from Alimentary/Metabolic
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.